Overbeck, Tobias R.

[["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Journal of Thoracic Oncology"],["dc.bibliographiccitation.volume","2"],["dc.contributor.author","Gauler, Thomas C."],["dc.contributor.author","Besse, Benjamin"],["dc.contributor.author","Meric, J. B."],["dc.contributor.author","Gounant, Valerie"],["dc.contributor.author","Fischer, B."],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Krissel, Heiko"],["dc.contributor.author","Laurent, Dirk"],["dc.contributor.author","Soria, Jean-Charles"],["dc.contributor.author","Eberhardt, Wilfried E."],["dc.date.accessioned","2018-11-07T11:00:17Z"],["dc.date.available","2018-11-07T11:00:17Z"],["dc.date.issued","2007"],["dc.format.extent","S358"],["dc.identifier.doi","10.1097/01.JTO.0000283188.24297.13"],["dc.identifier.isi","000248688600274"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50887"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.publisher.place","Philadelphia"],["dc.relation.issn","1556-0864"],["dc.title","Phase II open-label study to investigate PTK787/ZK 222584 (PTK/ZK) orally administered as a second-line monotherapy in patients with stage IIIB or stage IV non-small-cell lung cancer (NSCLC)"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","158"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Case Reports in Oncology"],["dc.bibliographiccitation.lastpage","163"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Schmitz, Katja"],["dc.contributor.author","Engelke, Christoph"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Hugo, Sara"],["dc.contributor.author","Kellner, Laura"],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Schildhaus, Hans-Ulrich"],["dc.date.accessioned","2020-12-10T18:37:47Z"],["dc.date.available","2020-12-10T18:37:47Z"],["dc.date.issued","2016"],["dc.identifier.doi","10.1159/000444745"],["dc.identifier.eissn","1662-6575"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77092"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Partial Response to First-Line Crizotinib in an Elderly Male Patient with ROS1 Translocation-Positive Lung Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","270"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Oncology"],["dc.bibliographiccitation.lastpage","278"],["dc.bibliographiccitation.volume","93"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Arnemann, Johanna"],["dc.contributor.author","Waldmann-Beushausen, Regina"],["dc.contributor.author","Schöndube, Friedrich A."],["dc.contributor.author","Reuter-Jessen, Kirsten"],["dc.contributor.author","Danner, Bernhard C."],["dc.contributor.author","Trümper, Lorenz"],["dc.date.accessioned","2019-01-29T11:57:51Z"],["dc.date.available","2019-01-29T11:57:51Z"],["dc.date.issued","2017"],["dc.description.abstract","ATP-binding cassette transport protein A3 (ABCA3) is expressed in non-small cell lung cancer (NSCLC). We hypothesize that high-level ABCA3 expression may have a negative prognostic impact in patients with NSCLC."],["dc.identifier.doi","10.1159/000477619"],["dc.identifier.pmid","28683465"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/57421"],["dc.language.iso","en"],["dc.notes.intern","DeepGreen Import"],["dc.notes.status","final"],["dc.publisher","S. Karger AG"],["dc.relation.eissn","1423-0232"],["dc.relation.issn","0030-2414"],["dc.rights","https://www.karger.com/Services/SiteLicenses"],["dc.title","ABCA3 Phenotype in Non-Small Cell Lung Cancer Indicates Poor Outcome"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","362"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Oncology"],["dc.bibliographiccitation.lastpage","370"],["dc.bibliographiccitation.volume","84"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Hupfeld, Timo"],["dc.contributor.author","Krause, Doris"],["dc.contributor.author","Waldmann-Beushausen, Regina"],["dc.contributor.author","Chapuy, Björn"],["dc.contributor.author","Guedenzoph, Bjoern"],["dc.contributor.author","Aung, Thiha"],["dc.contributor.author","Inagaki, Nobuya"],["dc.contributor.author","Schoendube, Friedrich Albert"],["dc.contributor.author","Danner, Bernhard Christoph"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Wulf, Gerald G."],["dc.date.accessioned","2018-11-07T09:29:56Z"],["dc.date.available","2018-11-07T09:29:56Z"],["dc.date.issued","2013"],["dc.description.abstract","Patients with advanced-stage bronchial cancer benefit from systemic cytostatic therapy, in particular from regimens integrating cisplatin and taxanes. However, eventual disease progression leads to a fatal outcome in most cases, originating from tumor cells resisting chemotherapy. We here show that the intracellular ATP-binding cassette transporter A3 (ABCA3), previously recognized as critical for the secretion of surfactant components from type 2 pneumocytes, is expressed in non-small-cell lung cancer (NSCLC) cells. With some heterogeneity in a given specimen, expression levels detected immunohistochemically in primary cancer tissue were highest in adenocarcinomas and lowest in small cell lung cancers. Genetic silencing of ABCA3 in the NSCLC cell line models A549, NCI-H1650 and NCI-H1975 significantly increased tumor cell susceptibility to the cytostatic effects of both cisplatin (in all cell lines) and paclitaxel (in two of three cell lines). Taken together, ABCA3 emerges as a modulator of NSCLC cell susceptibility to cytostatic therapy. Copyright (c) 2013 S. Karger AG, Basel"],["dc.description.sponsorship","Faculty of Medicine, Georg August University Gottingen, Germany"],["dc.identifier.doi","10.1159/000348884"],["dc.identifier.isi","000320219100007"],["dc.identifier.pmid","23689165"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10826"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/31175"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","0030-2414"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Intracellular ATP-Binding Cassette Transporter A3 is Expressed in Lung Cancer Cells and Modulates Susceptibility to Cisplatin and Paclitaxel"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","424"],["dc.bibliographiccitation.journal","BMC Cancer"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Schaefer, Inga-Marie"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Schweyer, Stefan"],["dc.contributor.author","Menke, Jan"],["dc.date.accessioned","2018-11-07T09:05:44Z"],["dc.date.available","2018-11-07T09:05:44Z"],["dc.date.issued","2012"],["dc.description.abstract","Background: Pulmonary carcinosarcoma is a biphasic tumour with an unfavourable prognosis. The differential diagnosis includes pulmonary blastoma and is often challenging. Case presentation: We here describe a case of blastomatoid pulmonary carcinosarcoma in a 58-year-old patient, who underwent surgical resection. Histopathological examination revealed immature glandular epithelium resembling high-grade fetal adenocarcinoma expressing epithelial markers and membranous beta-catenin, and blastomatoid spindle cells with partial rhabdomyosarcoma-like differentiation. Both elements expressed p53, MDM2, and cyclin-dependent kinase 4 (CDK4), but not thyroid-transcription factor 1 (TTF-1). Mutation analysis of KRAS, EGFR, and beta-catenin revealed no mutations. Comparative genomic hybridization detected +1q, +6p, +6q24qter, +8q, +11q12q14, +11q23qter, +12q12q21, +12q24qter, +17q, +20q, -5q14q23, -9p13pter, -13q21q21, and amplifications at 12q14q21, 15q24qter, 20q11q12. Conclusion: The observed molecular and cytogenetic findings may provide additional tools for the differential diagnosis of biphasic pulmonary neoplasms. Furthermore, TP53, MDM2, CDK4, and PTPN1 may be involved in tumourigenesis."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2012"],["dc.identifier.doi","10.1186/1471-2407-12-424"],["dc.identifier.isi","000312100800001"],["dc.identifier.pmid","23006472"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/8423"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/25394"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1471-2407"],["dc.rights","CC BY 2.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/2.0"],["dc.title","Blastomatoid pulmonary carcinosarcoma: report of a case with a review of the literature"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Clinical Infectious Diseases"],["dc.bibliographiccitation.volume","62"],["dc.contributor.author","Moessner, Rotraut"],["dc.contributor.author","Diering, Nina"],["dc.contributor.author","Bader, Oliver"],["dc.contributor.author","Forkel, Susann"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Gross, Uwe"],["dc.contributor.author","Grimbacher, Bodo"],["dc.contributor.author","Schoen, Michael Peter"],["dc.contributor.author","Buhl, Timo"],["dc.date.accessioned","2018-11-07T10:16:10Z"],["dc.date.available","2018-11-07T10:16:10Z"],["dc.date.issued","2016"],["dc.identifier.doi","10.1093/cid/ciw020"],["dc.identifier.isi","000374248700026"],["dc.identifier.pmid","26787170"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40985"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press Inc"],["dc.relation.issn","1537-6591"],["dc.relation.issn","1058-4838"],["dc.title","Ruxolitinib Induces Interleukin 17 and Ameliorates Chronic Mucocutaneous Candidiasis Caused by STAT1 Gain-of-Function Mutation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Journal of Thoracic Oncology"],["dc.bibliographiccitation.volume","4"],["dc.contributor.author","Felip, Enriqueta"],["dc.contributor.author","Massuti, Bartomeu"],["dc.contributor.author","Maestre, Jose Antonio"],["dc.contributor.author","Alonso, Guillermo"],["dc.contributor.author","Paniagua, Jose Manuel R."],["dc.contributor.author","Gonzalez-Larriba, Jose Luis"],["dc.contributor.author","Camps, Carlos"],["dc.contributor.author","Isla, Dolores"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Costas, Emma"],["dc.contributor.author","Sanchez, Jose Javier"],["dc.contributor.author","Rosell, Rafael"],["dc.date.accessioned","2018-11-07T11:25:09Z"],["dc.date.available","2018-11-07T11:25:09Z"],["dc.date.issued","2009"],["dc.format.extent","S283"],["dc.identifier.isi","000269496000278"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/56568"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.publisher.place","Philadelphia"],["dc.relation.issn","1556-1380"],["dc.relation.issn","1556-0864"],["dc.title","A phase III randomized trial of surgery (S) alone, or preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy followed by S, or S followed by adjuvant (adj) PC chemotherapy in early stage non-small cell lung cancer (NSCLC): NATCH follow-up data"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","179"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Dermatology"],["dc.bibliographiccitation.lastpage","182"],["dc.bibliographiccitation.volume","225"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Griesinger, Frank"],["dc.date.accessioned","2018-11-07T09:14:44Z"],["dc.date.available","2018-11-07T09:14:44Z"],["dc.date.issued","2012"],["dc.description.abstract","Erlotinib inhibits the tyrosine kinase of epidermal growth factor receptor (EGFR) and is successfully used in lung cancer treatment. EGFR is essential in skin development and function and may have a role in the pathogenesis of psoriasis. Cutaneous side effects are very common in patients treated with erlotinib, and therapeutic use of erlotinib in dermatological disorders has therefore not been considered. We report two cases of patients with lung cancer and concomitant psoriasis treated with erlotinib with complete resolution of the skin problems. We present a review of the current literature on the topic. Copyright (C) 2012 S. Karger AG, Basel"],["dc.description.sponsorship","Roche"],["dc.identifier.doi","10.1159/000342786"],["dc.identifier.isi","000311760700015"],["dc.identifier.pmid","23095682"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/9078"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/27489"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.relation.issn","1018-8665"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Two Cases of Psoriasis Responding to Erlotinib: Time to Revisiting Inhibition of Epidermal Growth Factor Receptor in Psoriasis Therapy?"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","944"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","New England Journal of Medicine"],["dc.bibliographiccitation.lastpage","957"],["dc.bibliographiccitation.volume","383"],["dc.contributor.author","Wolf, Jürgen"],["dc.contributor.author","Seto, Takashi"],["dc.contributor.author","Han, Ji-Youn"],["dc.contributor.author","Reguart, Noemi"],["dc.contributor.author","Garon, Edward B."],["dc.contributor.author","Groen, Harry J.M."],["dc.contributor.author","Tan, Daniel S.W."],["dc.contributor.author","Hida, Toyoaki"],["dc.contributor.author","de Jonge, Maja"],["dc.contributor.author","Orlov, Sergey V."],["dc.contributor.author","Smit, Egbert F."],["dc.contributor.author","Souquet, Pierre-Jean"],["dc.contributor.author","Vansteenkiste, Johan"],["dc.contributor.author","Hochmair, Maximilian"],["dc.contributor.author","Felip, Enriqueta"],["dc.contributor.author","Nishio, Makoto"],["dc.contributor.author","Thomas, Michael"],["dc.contributor.author","Ohashi, Kadoaki"],["dc.contributor.author","Toyozawa, Ryo"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","de Marinis, Filippo"],["dc.contributor.author","Kim, Tae-Min"],["dc.contributor.author","Laack, Eckart"],["dc.contributor.author","Robeva, Anna"],["dc.contributor.author","Le Mouhaer, Sylvie"],["dc.contributor.author","Waldron-Lynch, Maeve"],["dc.contributor.author","Sankaran, Banu"],["dc.contributor.author","Balbin, O. Alejandro"],["dc.contributor.author","Cui, Xiaoming"],["dc.contributor.author","Giovannini, Monica"],["dc.contributor.author","Akimov, Mikhail"],["dc.contributor.author","Heist, Rebecca S."],["dc.date.accessioned","2021-04-14T08:23:04Z"],["dc.date.available","2021-04-14T08:23:04Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1056/NEJMoa2002787"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/80794"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1533-4406"],["dc.relation.issn","0028-4793"],["dc.title","Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","81"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal der Deutschen Dermatologischen Gesellschaft"],["dc.bibliographiccitation.lastpage","83"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Claßen, Anna"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Perske, Christina"],["dc.contributor.author","Overbeck, Tobias"],["dc.contributor.author","Bertsch, Hans Peter"],["dc.contributor.author","Schön, Michael P."],["dc.contributor.author","Lippert, Undine"],["dc.date.accessioned","2020-12-10T18:27:17Z"],["dc.date.available","2020-12-10T18:27:17Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1111/ddg.13398"],["dc.identifier.issn","1610-0379"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/76294"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Leukemia cutis in a patient with chronic myelomonocytic leukemia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]